GSK Acquires CMG1A46 From Chimagen Biosciences For $300M To Boost Immunology Pipeline, Targeting B Cell-Driven Autoimmune Diseases Like Lupus; Chimagen Eligible For Additional $550M In Milestone Payments
GSK Acquires CMG1A46 From Chimagen Biosciences For $300M To Boost Immunology Pipeline, Targeting B Cell-Driven Autoimmune Diseases Like Lupus; Chimagen Eligible For Additional $550M In Milestone Payments
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.